Boosting Mesothelioma Survival with VEGF-Inhibitor
The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment. Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy. What is Cediranib? Cediranib, an oral drug made by Astra Zeneca, is a powerful … Continue reading Boosting Mesothelioma Survival with VEGF-Inhibitor
Standardization Needed for Peritoneal Mesothelioma Treatment
Mesothelioma researchers in Belgium and the US have some good news and some bad news about peritoneal mesothelioma treatment. The good news is that the combination of cytoreductive surgery to remove the mesothelioma tumor and intraperitoneal chemotherapy (HIPEC) to kill residual cancer cells improves mesothelioma survival. Overall, the method is so effective that the authors say the combination should now be considered standard of care … Continue reading Standardization Needed for Peritoneal Mesothelioma Treatment
VEGF-Inhibitor Looks Promising for Malignant Mesothelioma
There is more encouraging news about the monoclonal antibody bevacizumab (Avastin) and its potential to boost the effectiveness of chemotherapy for people with malignant pleural mesothelioma. A pair of oncology researchers from Texas have just released their summary of the the most recent published studies on bevacizumab. They conclude that, for the right patients, bevacizumab may improve mesothelioma outcomes and extend survival by blocking tumor blood … Continue reading VEGF-Inhibitor Looks Promising for Malignant Mesothelioma
Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients
Mesothelioma patients who experience a recurrence of their asbestos cancer after radical surgery may live longer if they undergo additional rounds of chemotherapy. That conclusion comes from a group of Japanese researchers who performed a retrospective review of 59 consecutive pleural mesothelioma patients who had multimodal mesothelioma treatment that included extrapleural pneumonectomy (EPP) surgery. Study subjects had been treated for malignant mesothelioma at Hyogo College … Continue reading Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients
New Combination Treatment for Rare Mesothelioma Subtypes
An enzyme shown to help fight melanoma and liver cancer may offer new hope to patients with some of the most treatment-resistant mesothelioma tumors. Malignant mesothelioma is a rare, asbestos-linked cancer of internal membranes. Although all forms are highly resistant to standard cancer therapies, the sarcomatoid and biphasic subtypes – which are the rarest forms of mesothelioma – typically carry the worst prognosis. But a … Continue reading New Combination Treatment for Rare Mesothelioma Subtypes
New Drug Delivery System Doubles Mesothelioma Survival
A new method for delivering cancer-fighting drugs directly into mesothelioma tumors has been shown to more that double mesothelioma survival in a new animal study. Surgeons, pathologists, biomedical engineers and chemists from Boston University and Harvard Medical School used specially-formulated expanding nanoparticles to deliver high doses of the drug paclitaxel into mice with malignant mesothelioma. By loading the drug into nanoparticles that expand in the … Continue reading New Drug Delivery System Doubles Mesothelioma Survival
New Mesothelioma Immunotherapies Target Key Protein
The cell-surface glycoprotein mesothelin is poised to be a key part of several new immunotherapy approaches for the treatment of malignant pleural mesothelioma, a treatment-resistant cancer caused by asbestos. A team of top mesothelioma researchers with the National Cancer Institute’s Center for Cancer Research recently published their analysis of several ongoing studies of therapies that target mesothelin in mesothelioma treatment. Mesothelin’s Relationship to Mesothelioma Mesothelin is … Continue reading New Mesothelioma Immunotherapies Target Key Protein
Study Finds Chemotherapy Maximizes Odds of Mesothelioma Survival
A large US study of mesothelioma patients confirms what other studies have suggested: Mesothelioma patients who have chemotherapy live longer than those who don’t, and multimodal therapy is the best way to improve overall mesothelioma survival. The study utilized data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database and included 1,625 Medicare patients with a diagnosis or either peritoneal or pleural … Continue reading Study Finds Chemotherapy Maximizes Odds of Mesothelioma Survival
Mesothelioma Treatment News: Novel Immunotherapy Drug Featured at International Symposium
A promising immunotherapy drug made from a deactivated cold virus has cleared another hurdle on its way to becoming a viable new treatment for malignant mesothelioma. Scientists with the Norway-based company that makes ONCOS-102 presented their most recent mesothelioma research data to colleagues at a symposium hosted by the International Society of Stem Cell Research and the European Society of Gene and Cell Therapy in October. … Continue reading Mesothelioma Treatment News: Novel Immunotherapy Drug Featured at International Symposium
Mesothelioma Growth Slowed by Breast Cancer Drug
A drug most often associated with the treatment and prevention of breast cancer may offer a new way to treat pleural mesothelioma, too. A new study conducted by Ireland’s Royal College of Surgeons and published in the medical journal Anticancer Research focuses on tamoxifen as a novel mesothelioma therapy. How Tamoxifen Works Tamoxifen helps fight breast cancer and protect high-risk women from getting it by … Continue reading Mesothelioma Growth Slowed by Breast Cancer Drug
“My Name is Paul Kraus and I Have Survived Mesothelioma for Nearly 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!